D4476 5 mg | 99.80%
TargetMol
D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).
More Information Supplier PageD4476
Search Results
D4476 50 mg | 99.80%
TargetMol
D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).
More Information Supplier PageD4476
D4476 25 mg | 99.80%
TargetMol
D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).
More Information Supplier PageD4476
D4476 10 mg | 99.80%
TargetMol
D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).
More Information Supplier PageD4476
Olverembatinib dimesylate 5 mg | 99.81%
TargetMol
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
More Information Supplier PageOlverembatinib dimesylate
Olverembatinib dimesylate 50 mg | 99.81%
TargetMol
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
More Information Supplier PageOlverembatinib dimesylate
Dacinostat 50 mg | 95.28%
TargetMol
LAQ824 (Dacinostat) is a novel HDAC inhibitor with IC50 of 32 nM and is an activator of the p21 promoter.
More Information Supplier PageDacinostat
Dacinostat 5 mg | 95.28%
TargetMol
LAQ824 (Dacinostat) is a novel HDAC inhibitor with IC50 of 32 nM and is an activator of the p21 promoter.
More Information Supplier PageDacinostat
Baricitinib 5 mg | Purity Not Available
TargetMol
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
More Information Supplier PageBaricitinib
Baricitinib 10 mg | Purity Not Available
TargetMol
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
More Information Supplier PageBaricitinib